새로운 항우울제들의 약물 상호작용

Abstract

Newer antidepressants frequently used for the treatment of depression are serotonin-selective reuptake inhibitors(fluoxetine, paroxetine, sertraline), serotonin-norepinephrine reuptake inhibitor(venlafaxine), postsynaptic serotonin antagonist-presynaptic serotonin reuptake inhibitor(nefazodone), presynaptic-postsynaptic noradrenergic serotonergic receptor antagonist(mirtazapine). Many of these drugs are potent inhibitors of the cytochrome P-450 enzymes(CYPs) of the liver. Most relevant CYPs of these antidepressants are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. CYP inhibition may affect the metabolism of drugs, so that the clinicians must remember the drug-drug interaction to avoid the adverse side effects. Herein reviewed the primer on drug metabolism, specific CYPs that are important in the use of antidepressant drugs and drug-drug interaction of antidepressants.